IL17A and oral lichen planus: Additionally, therapies such as Alefacept and agents targeting IL-17 and related pathways (e.g., ustekinumab, guselkumab, secukinumab, and tildrakizumab) have demonstrated efficacy, particularly in reducing the Th1 and Th17/Tc17 cellular mucosal infiltrate, suggesting a key role for IL-17-producing T cells in OLP pathogenesis.